

Cancer Genetics Career Development Program Trainee Profiles

Current Trainees



Jessica N. Clague DeHart, PhD, MPH
May 2010 – Present

Dr. Clague received a Bachelors of Science in health promotion and disease prevention from the University of Southern California and an MPH in chronic disease epidemiology from Yale University. She graduated with her PhD in cancer epidemiology from the University of Texas and M.D. Anderson Cancer Center in 2010. Her previous research focused on identifying clinical and epidemiologic profiles and biomarkers that could be used to help predict cancer risk and outcomes, specifically among tobacco-related cancers. Her current training and research in the CGCDP center on interdisciplinary cancer epidemiology, combining epidemiology and biostatistics with clinical genetics in order to develop individualized cancer risk prediction models. She already has a first authored publication developed during the

first six months of CGCDP traineeship. Dr. Clague is a member of the American Society of Human Genetics, the American Association of Cancer Research, and the American Society of Preventive Oncology.

Peer-Reviewed Publications

Clague J, Blazer K, Collie CL, Kam LC, Kuratani D, Laird S, Sabado P, Warren K, Chang S. A Meeting report from "Future Directions in Cancer Prevention & Control: Workforce Implications for Training, Practice, & Policy" symposium. Cancer Epidemiology Biomarkers Prevention, 2010, 19(6):1655-60.

Chen M, Hildebrandt MAT, **Clague J**, Kamat A, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garci-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Pathway Genes Affect Clinical Outcomes in Non-muscle-invasive Bladder Cancer. Cancer Prevention Research (Ahead of print).

Lin J, Horikawa Y, Tamboli P, **Clague J**, Wood CG, Wu X. Genetic Variations in MicroRNA-related Genes are Associated with Survival and Recurrence in Patients with Renal Cell Carcinoma. Carcinogenesis (Ahead of print).

Clague J, Lippman SM, Yang H, Hildebrandt MAT, Lee J, Wu X. Genetic Variations in MicroRNA Genes and Risk of Oral Premalignant Lesions. Molecular Carcinogenesis, 2010, 49(2):183-9.

Clague J, Cinciripini P, Blalock J, Wu X, Hudmon K. The D2 dopamine receptor gene and nicotine dependence among bladder cancer patients and controls. Behavior Genetics, 2010, 40(1):49-58.

Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of Renal Cell Carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18(3):801-7.

Clague J, Shao L, Lin J, Chang S, Zhu Y, Wang W, Wood CG, Wu X. NNKOAc sensitivity as a predictive marker for renal cancer risk. Carcinogenesis, 2009, 30(4):706-10.



Arelis Martir-Negron, MD
July 2010 – Present

Dr. Martir-Negron is a native of Puerto Rico. She received a Bachelor of Science degree in Biology from the University of Puerto Rico, Mayaguez Campus. She received her Medical degree from the Universidad Autonoma de Guadalajara Mexico. She completed her Internal Medicine training in Ramon E. Betances University Hospital, Ponce School of Medicine, Puerto Rico. The lack of a comprehensive cancer genetics program and the paucity of Adult Medicine physicians trained in Genetics was the reason she became interested in Clinical Genetics. After completing her residency she she began a Medical Genetics residency at The University of Alabama at Birmingham. Her research project during the residency was “Creatine deficiency syndromes: retrospective analysis of a phenotypically suspicious patient cohort”. Her interest in clinical genetics, cancer and research brought her to

the Clinical Cancer Genetics division at City of Hope. Dr. Martir-Negron was accepted to the Cancer Genetics Career Development Program in July 2010. She completed the Intensive Course in Clinical Cancer Genetics at City of Hope on August 2010. She is currently taking Principles of Biostatistics with Dr. Azen at The University Southern California. She is also participating in the methodology Observational Study course in The Clinical Investigation Training program at City of Hope. The coursework in the fellowship is preparing her to be an independent researcher. Since starting her fellowship she has had the opportunity to participate in and attend lectures and working groups in Hematology – Oncology and Cancer genetics.

Dr. Martir will be involved in projects that explore ancestry informed genetic cancer risk assessment strategies and address disparities among underserved Latinas with hereditary breast and ovarian cancer. She will study *BRCA* mutations from a consortium of high-risk clinics serving Hispanic populations, from published literature and public databases, and from additional population-based cohorts. In addition, she will conduct secondary analyses on a project aimed at evaluating the effect of genetic cancer risk assessment on a population of underserved women of predominately Hispanic descent residing in Southern California and examining a social-cognitive-cultural model of perceived access to care that can guide future interventions with this population. Dr. Martir-Negron has a special interest in serving her community in Cancer risk assessment and prevention.

Dr. Martir-Negron is a Diplomate of the American college of Internal Medicine. She is a member of The American College of Physician and Puerto Rico Medical College. She is licensed to practice Medicine in Puerto Rico, Alabama and California.



Laura Beamer, D.N.P., C.N.P., C.N.S.
August 2009 – Present

Dr. Beamer is a doctoral nurse fellow in Clinical Cancer Genetics that is nationally and internationally recognized as an expert in adult oncology and healthcare ethics. She is the only nurse certified as both an AOCNP and AOCNS. As a Clinical Cancer Genetics fellow in the Cancer Genetics Career Development Program, Dr. Beamer is applying for recognition as an Advanced Practice Nurse in Genetics through the Genetic Nursing Credentialing Commission. Her research focuses on the prevention of

familial and hereditary colon cancer through lifestyle behaviors, perceptions of cancer prevention efficacy, the process of follow-up care after abnormal colorectal cancer tumor tests, and system behavior regarding genetic testing of colorectal tumors. She has presented at international and national oncology and genetics conferences. Dr. Beamer has co-authored several standards and position statements for the Oncology Nursing Society (ONS). She has served as a guest reviewer for *Qualitative Healthcare Research*. Dr. Beamer is the Coordinator of the ONS Ethics Special Interest Group. She volunteers for the American Cancer Society; helped build a house in Glendale, CA with Habit for Humanity; and is an ordained priest.

Previous Trainees



April Sorrell, MD
August 2007 – September 2009

Since completing the CGCDP Program, Dr. Sorrell has accepted a position as Assistant Professor, City of Hope Department of Pediatrics, where in addition to furthering her current research endeavors (below), she has initiated a pediatric cancer genetics program and is developing research collaborations through a recently formed international Li-Fraumeni consortium. Ongoing efforts: A manuscript reporting the results of her collaboration in characterizing the 3p25 run-on mutation *X214L* titled, “*Clinical and functional properties of novel VHL mutation (X214L) consistent with type 2A phenotype and low risk of renal cell carcinoma*” was accepted for publication in *Clinical Cancer Genetics* (in press). Additional research collaborations with molecular pathology faculty

include analyses of BRCA expression by IHC to develop improved methods for screening for germline *BRCA* mutations, utilizing multi-tissue FFPE blocks with more than 100 breast cancers from *BRCA* carriers. In addition, she is the PI for the Children’s Oncology Group study (COG AAML08B1): Biology Study of Transient Myeloproliferative Disorder(TMD) in Children with Down Syndrome (DS). Activated on 2/23/2009, the study is currently accruing patients. Development of a related research proposal, preliminary data, and grant submission for an investigator-initiated project entitled: “Age-specific DNA Methylation patterns in human Trisomy 21 cells/tissues may associate with leukemia and predict a mutator phenotype in infants prior to clinical evidence of leukemia” is in progress.

Peer-Reviewed Publications

Sorrell AD, Lee S, Stolle C, Ellenhorn J, Grix A, Kaelin WG Jr, Weitzel JN. Clinical and functional properties of novel VHL mutation (*X214L*) consistent with type 2A phenotype and low risk of renal cell carcinoma. *Clin Genet*. 2010 May 13. [Epub ahead of print] PubMed PMID: 20560986.

Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, **Sorrell AD**, Masterson M, Bleyer A, Gaynon PS. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children’s Oncology Group CCG-1952 clinical trial. *Blood*. 2010 Apr 8;115(14):2740-8. Epub 2010 Feb 1. PubMed PMID: 20124218; PubMed Central PMCID: PMC2854423.

Bhat R, Malinge S, Gamis AS, **Sorrell AD**, Hilden JM, Ketterling RP, Paietta E, Tallman MS, Crispino JD. Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia. *Leukemia*. 2009 Nov;23(11):2159-60. PubMed PMID: 19657363



Dr. Edwards (right)

Quanetta Edwards, PhD, FNP, WHCNP
August 2005 – August 2007

Dr. Edwards's research in the CGCDP program was focused on multiethnic comparisons of mammography uptake. Dr. Edwards is currently employed as Associate Professor at Western University of Health Sciences in the College of Graduate Nursing, located in Pomona, CA. Previous to that she was recruited to an Associate Professor position at California State University, Fullerton, Department of Nursing Research/Administration. Dr. Edwards also serves as a breast cancer prevention consultant and reviewer for nursing research with the American Academy of Nurse Practitioners. She continues her research in health disparities and breast cancer. Dr. Edwards is currently preparing an R01 for submission to the

NIH/NINR related to *MMP2 gene expression and differences in overall metastasis and survival among breast cancer patients*. Her post training peer-reviewed authorship includes findings from CGCDP-related research.

Peer-Reviewed Publications

Edwards QT, Seibert D. Pre- and posttest evaluation of a breast cancer risk assessment program for nurse practitioners. *J Am Acad Nurse Pract*. 2010 Jul;22(7):376-81. PubMed PMID: 20590960.

Edwards QT, Li A, Pike MC, Kolonel L, Henderson BE, McKean-Cowdin R. Patterns of regular use of mammography--body weight and ethnicity: the Multiethnic Cohort. *J Am Acad Nurse Pract*. 2010 Mar;22(3):162-9. PubMed PMID: 20236401.

Edwards QT, Maradiegue A, Seibert D, Saunders-Goldson S, Humphreys S. Breast cancer risk elements and nurse practitioners' knowledge, use, and perceived comfort level of breast cancer risk assessment. *J Am Acad Nurse Pract*. 2009 May;21(5):270-7. PubMed PMID: 19432911.

Edwards QT, Li AX, Pike MC, Kolonel LN, Ursin G, Henderson BE, McKean-Cowdin R. Ethnic differences in the use of regular mammography: the multiethnic cohort. *Breast Cancer Res Treat*. 2009 May;115(1):163-70. Epub 2008 May 21. PubMed PMID:18493849.

Maradiegue A, Jasperson K, **Edwards QT**, Lowstuter K, Weitzel J. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners. *J Am Acad Nurse Pract*. 2008 Feb;20(2):76-84. Review. PubMed PMID: 18271762.

Edwards QT, Seibert D, Maradiegue A, MacDonald D, Jasperson K, Lowstuter K, Weitzel J. Breast cancer and the family tree. An issue for all practice settings. *Adv Nurse Pract*. 2007 May;15(5):34-41; quiz 41-2. PubMed PMID: 20000211.

Seibert D, **Edwards QT**, Maradiegue A. Integrating genetics into advanced practice nursing curriculum: strategies for success. *Community Genet*. 2007;10(1):45-51. PubMed PMID: 17167251.



Kory Jasperson, MS, CGC
June 2005 – June 2006

Kory Jasperson is a board-certified genetic counselor with a master's degree in genetic counseling from California State University Northridge and a bachelor's degree in genetics from University of California Davis. Since completing CGCDP traineeship, Mr. Jasperson has worked as a licensed genetic counselor at Huntsman Cancer Institute since 2006. His clinical and research collaborations at Huntsman focus on hereditary gastrointestinal cancers. He has first-authored 5 and co-authored 5 peer-reviewed publications. He is a member of the NCCN Colorectal Cancer

Screening advisory panel. Among several speaking engagements is his participation as guest faculty in March 2009 for City of Hope's first patient reunion conference for families with hereditary cancer risk.

Peer-Reviewed Publications

Kory W. Jasperson, Wade S. Samowitz and Randall W. Burt. Constitutional mismatch repair-deficiency syndrome presenting as colonic adenomatous polyposis: clues from the skin. Accepted manuscript online: 16 SEP 2010 12:12AM EST | DOI: 10.1111/j.1399-0004.2010.01543.

Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. *Gastroenterology*. 2010 Jun;138(6):2044-58. Review. PubMed PMID: 20420945.

Burt RW, **Jasperson KW**. *APC*-Associated Polyposis Conditions. 1998 Dec 18 [updated 2008 Jul 24]. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. Available from <http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=fap> PubMed PMID: 20301519.

Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, **Jasperson K**, Lazenby AJ, Lynch PM, Martin EW Jr, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D; NCCN. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. *J Natl Compr Canc Netw*. 2010 Jan;8(1):8-61. PubMed PMID: 20064289.

Jasperson KW, Vu TM, Schwab AL, Neklason DW, Rodriguez-Bigas MA, Burt RW, Weitzel JN. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. *Fam Cancer*. 2010 Jun;9(2):99-107. PubMed PMID: 19731080.

Gammon A, **Jasperson K**, Kohlmann W, Burt RW. Hamartomatous polyposis syndromes. *Best Pract Res Clin Gastroenterol*. 2009;23(2):219-31. Review. PubMed PMID:19414148; PubMed Central PMCID: PMC2678968.

Maradiegue A, **Jasperson K**, Edwards QT, Lowstuter K, Weitzel J. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners. *J Am Acad Nurse Pract*. 2008 Feb;20(2):76-84. Review. PubMed PMID: 18271762.

Jasperson KW, Blazer KR, Lowstuter K, Weitzel JN. Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. *Fam Cancer*. 2008;7(4):281-5. Epub 2008 Jan 6. PubMed PMID: 18176851.

Edwards QT, Seibert D, Maradiegue A, MacDonald D, **Jasperson K**, Lowstuter K, Weitzel J. Breast cancer and the family tree. An issue for all practice settings. *Adv Nurse Pract*. 2007 May;15(5):34-41; quiz 41-2. PubMed PMID: 20000211.

Jasperson KW, Lowstuter K, Weitzel JN. Assessing the predictive accuracy of hMLH1 and hMSH2 mutation probability models. *J Genet Couns*. 2006 Oct;15(5):339-47. PubMed PMID: 16969708.



Dr. Mai (left) pictured with Co-Fellow, Cory Jaspersperson (right)

Phuong Mai, MD, MS
July 2004 – July 2006

Since completing the CGCDP program, Dr. Mai accepted a clinical/research position as Staff Physician with the National Cancer Institute, Clinical Genetics Branch. CGCDP-Initiated research projects included: 1) Descriptive epidemiology study on subsite distribution of colorectal cancer cases in different racial/ethnic groups using data from the LA Cancer Surveillance Program, 2) CCG database – study of prevalence of bilateral and unilateral mastectomy at time of GCRA, and 3) California teacher health study – Association between physical activities and colon cancer.

Dr. Mai graduated *Summa Cum Laude* from the University Houston in 1993, and received her M.D. degree from the University of Texas Medical Branch in Galveston in 1997. She completed her residency in Internal Medicine at Tulane University Medical Center in 2000, and her Medical Oncology fellowship at the University of Texas Health Science Center at San Antonio in 2004. During that fellowship, she simultaneously earned a Master of Science degree in Clinical Investigation. She is board-certified in Internal Medicine and Medical Oncology. Dr. Mai joined the Clinical Genetics Branch of the NCI Division of Cancer Epidemiology and Genetics in October 2006, where she is involved in a number of epidemiologic and clinical studies aimed at better understanding familial cancer syndromes, including hereditary breast/ovarian cancer and familial testicular cancer. Dr. Mai's research interests include the effects of behavioral factors on cancer risks, early detection and intervention in populations at increased risk of specific cancers, particularly women at increased genetic risk of ovarian cancer, and genetic modifiers of cancer risk.

Dr. Mai is currently lead investigator on the *Multidisciplinary Study of Hereditary Breast/Ovarian Cancer* (Protocol Number: 02-C-0212); and co-investigator on the *National Ovarian Cancer Prevention and Early Detection Study* (Protocol Number: 02-C-0268) and the *Multidisciplinary Study of Familial Testicular Cancer* (Protocol Number: 02-C-0178). In addition to two publications from her work in the CGCDP, her post training peer-reviewed authorship includes 7 first-authored and 13 co-authored publications.

Peer-Reviewed Publications

Greene MH, **Mai PL**, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? *Am J Obstet Gynecol*. 2010 Jul 7. [Epub ahead of print] PubMed PMID: 20619389.

Korde LA, Mueller CM, Loud JT, Struewing JP, Nichols K, Greene MH, **Mai PL**. No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. *Breast Cancer Res Treat*, 2010 May 11.[Epub ahead of print]

Gail MH, **Mai PL**. Comparing breast cancer risk assessment models. *J Natl Cancer Inst*. 2010 May 19;102(10):665-8. Epub 2010 Apr 28.

Greene MH, Kratz CP, **Mai PL**, Mueller C, Peters JA, Bratslavsky G, Ling A, Choyke PM, Premkumar A, Bracci J, Watkins RJ, McMaster ML, Korde LA. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. *Endocr Relat Cancer*. 2010 Mar 8;17(2):R109-21. Print 2010 Jun. Review. PubMed PMID: 20228134.

Wideroff L, Garceau AO, Greene MH, Dunn M, McNeel T, **Mai P**, Willis G, Gonsalves L, Martin M, Graubard BI. Coherence and completeness of population-based family cancer reports. *Cancer Epidemiol Biomarkers Prev*. 2010 Mar;19(3):799-810. Epub 2010 Feb 16. PubMed PMID: 20160272.

Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, **Mai PL**, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH. Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. *Breast Cancer Res Treat*. 2010 Feb 4. [Epub ahead of print] PubMed PMID: 20130984.

Mai PL, Wideroff L, Greene MH, Graubard BI: Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study. *In press*

Mai PL, Chen B, Tucker K et al.: Younger Age at Diagnosis for Familial Malignant Testicular Germ Cell Tumor. *Familial Cancer*, 2009; 8:451-456.

Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S, KConFab, Neuhausen SL, Couch F, Radice P, Szabo SI, Greene MH, **Mai PL**, Rennert G, Lejbkowitz F, et al., on behalf of CIMBA. Evaluation of a candidate breast cancer associated SNP in *ERCC4* as a phenotypic modifier in *BRCA1/2* mutation carriers. Results from the Consortium of Investigators of Modifiers of *BRCA1/BRCA2* (CIMBA). *Brit J Cancer*, 2009; 101: 2048-2054

Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, **Mai PL**, et al., on behalf of CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet*, 2009, Epub

Greene MH, **Mai PL**. What Have We Learned from Risk-Reducing Salpingo-oophorectomy? *JNCI*, 2009; 101:70-01

Mai PL, Rapley EA, ITCLC Co-authors, Greene MH: The International Testicular Cancer Linkage Consortium: A Clinicopathologic Descriptive Analysis of 461 Familial Malignant Testicular Germ Cell Tumor Kindred. *Urol Oncol*, 2009, Epub

Mai PL, Chatterjee N, Hartge P, Tucker MA, Brody L, Struewing JP, Wacholder S: Potential excess mortality in *BRCA1/2* mutation carriers beyond breast, ovarian, and prostate cancers. *PLoS ONE* 4(3): e4812. doi:10.1371/journal.pone.0004812

Greene, M.H., M. Piedmonte, D. Alberts, M. Gail, M. Hensley, Z. Miner, **P.L. Mai**, J. Loud, G. Rodriguez, J. Basil, J. Boggess, P.E. Schwartz, J.L. Kelley, K.E. Wakeley, L. Minasian and S. Skates. *A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study*. *Cancer Epidemiol Biomarkers Prev*, 2008. 17(3): p. 594-604.

Mai, P. L., Lagos, V. I., Palomares, M. R., & Weitzel, J. N. (2008). Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. *Ann Surg Oncol*, 15(12), 3415-3421.

Torkko KC, van Bokhoven A, **Mai P**, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, and Leach RJ (2008) *VDR* and *SRD5A2* Polymorphisms Combine to Increase Risk for Prostate Cancer in Non-Hispanic White and Hispanic White Men. *Clin Cancer Res*, 14: 3223-3229

Mueller CM, **Mai PL**, Bucher J, Peters JA, Loud JT, Greene MH. (2008) Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. *BMC Complement Altern Med* 8:17

Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, **Mai PL**, Loud J, Minasian L, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Skates SJ. (2008) GOG-199: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer. Design and baseline characteristics – A GOG Study. *Cancer Epidemiol Biomarkers Prev*, 17: 594-604

Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis Ca, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH (2007) A possible new syndrome with pituitary adenoma, colonic polyposis,

lipomatosis, lentiginos and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep, 1:9

Mai PL, Sullivan-Halley J, Ursin G, Stram D, Deapen D, Villaluna D, Horn-Ross P, Clarke CA, Reynolds P, Ross RK, West DW, Anton-Culver H, Ziogas A, Bernstein L (2007) Physical Activity and Colon Cancer Risk in the California Teachers Study (CTS). Cancer Epidemiol Biomarkers Prev 16:517-25



Barbara Sarter, PhD, APRN
July 2003 – November 2004

Dr. Sarter's preliminary work on her CGCDP-funded research in the design and conduct of laboratory assays of herbs as potential aromatase inhibitors (with the aim of identifying nutritional cancer prevention strategies) was presented and a grant proposal related to this project was submitted to the UCLA-GCRC. A K07 proposal on related work and an epidemiology project (Singapore Chinese Health Study) was also submitted.

Dr. Sarter currently holds a faculty position at the University of San Diego after two decades at the University of Southern California (USC). She founded the Family Nurse Practitioner Program at USC's School of Nursing. Prior to joining the USD faculty, she was Associate Professor of Family Medicine at USC, and Associate Director of LA Net, a Practice-Based Research Network dedicated to improving healthcare in Los Angeles' underserved populations. Dr. Sarter received her PhD in Nursing Theory and Research from New York University and her Family Nurse Practitioner certificate from UCLA. In 2008 she spent six months in Calcutta, India, studying and conducting clinical research on homeopathic therapeutics at the PBH Research Foundation. She is on the Fulbright Foundation Senior Specialist Roster and has frequently been invited as a Visiting Professor at the National Taipei College of Nursing in Taipei, Taiwan. Barbara has three published books, one of which, Paths to Knowledge, won the American Journal of Nursing Book of the Year award. Her most recent book, Evolutionary Healing, presents a broad philosophy of health that forms the foundation of her practice and research. She has published many research articles and abstracts on nutritional prevention of cancer and heart disease, and on outcomes of homeopathic treatment.

She maintains an active practice in integrative primary health care in addition to her teaching and research, and believes that her practice forms an essential foundation for all of her academic activities.

Peer-Reviewed Publications

Sarter B, Campbell TC, Fuhrman J. Effect of a high nutrient density diet on long-term weight loss: a retrospective chart review. Altern Ther Health Med. 2008 May-Jun;14(3):48-53. PubMed PMID: 18517106.

Sarter B, Long TI, Tsong WH, Koh WP, Yu MC, Laird PW. Sex differential in methylation patterns of selected genes in Singapore Chinese. Hum Genet. 2005 Aug;117(4):402-3. Epub 2005 Jun 1. PubMed PMID: 15928902.



Melanie Palomares, MD, MS
October 2003 – September 2004

Dr. Palomares is a medical oncologist and epidemiologist who is a specialist in cancer prevention. Subsequent to CGCDP traineeship, she was awarded a DOD Breast Cancer Research Career Award. She is currently Assistant Professor in the Departments of Population Sciences and Medical Oncology & Therapeutics Research at City of Hope. Her research focus is in breast cancer prevention and early detection, and she has particular expertise in breast cancer chemoprevention trials, including trials using natural products.

Dr. Palomares was recently awarded a 5-year, \$3.3 million R01 grant from the National Cancer Institute. She is the Principal Investigator of a multicenter study that will investigate whether a low daily dose of tamoxifen will decrease the risk of breast cancer among women who have been treated for Hodgkin's lymphoma in childhood, adolescence or early adulthood. The study involves 300 healthy, female Hodgkin's lymphoma survivors at five institutions across the US and Canada who received radiotherapy for lymphoma before age 30.

Peer-Reviewed Publications

Dunbier AK, Hong Y, Masri S, Brown KA, Sabnis GJ, Palomares MR. Progress in aromatase research and identification of key future directions. *J Steroid Biochem Mol Biol*. 2010 Feb 28;118(4-5):311-5. Epub 2009 Sep 22. PubMed PMID: 19778609.

Mai PL, Lagos VI, Palomares MR, Weitzel JN. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. *Ann Surg Oncol*. 2008 Dec;15(12):3415-21. Epub 2008 Oct 4. PubMed PMID: 18836779.

Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, Palomares MR, Lowstuter KJ, MacDonald DJ. Limited family structure and BRCA gene mutation status in single cases of breast cancer. *JAMA*. 2007 Jun 20;297(23):2587-95. PubMed PMID: 17579227.

Palomares MR, Machia JR, Lehman CD, Daling JR, McTiernan A. Mammographic density correlation with Gail model breast cancer risk estimates and component risk factors. *Cancer Epidemiol Biomarkers Prev*. 2006 Jul;15(7):1324-30. PubMed PMID: 16835331.

Palomares MR, Paz B, Weitzel JN. Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. *J Clin Oncol*. 2005 May 1;23(13):3165-6; author reply 3166-7. PubMed PMID: 15860891.



Oswaldo Schirripa, MD
July 2002 – June 2004

Dr. Schirripa's research during traineeship was in translational research project with a focus on prostate tumorigenesis and the role of CEACAM-1 in lumen and duct formation. After CGCD Ptraineeship, he took a Research Assistant Professor position at a private lab in Sylmar, CA.

Peer-Reviewed Publications

Habeeb O, Goodglick L, Soslow RA, Rao RG, Gordon LK, **Schirripa O**, Horvath S, Braun J, Seligson DB, Wadehra M. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. *Cancer*. 2010 Jun 24. [Epub ahead of print] PubMed PMID: 20578181.

Patel, A. A., Gupta, D., Seligson, D., Hattab, E. M., Balis, U. J., Ulbright, T. M., Kohane, I. S., Berman, J. J., Gilbertson, J. R., Dry, S., **Schirripa, O.**, Yu, H., Becich, M. J., Parwani, A. V. (2007). Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). *BMC Cancer*, 7, 37.